Novavax, Inc. (NASDAQ:NVAX) shares collapsed nearly 82% this morning, after the vaccine maker announced that RESOLVE, a Phase III trial in older adults with its RSV …
Novavax, Inc. (NASDAQ:NVAX) announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults.
Guggenheim analyst William Tanner was out pounding the table on Novavax, Inc. (NASDAQ:NVAX) Friday, reiterating a Buy rating and price target of $25, which implies an …
In a research report issued today, FBR analyst Vernon Bernardino reiterated an Outperform rating on shears of Novavax, Inc. (NASDAQ:NVAX), with a price target …
Novavax, Inc. (NASDAQ:NVAX) announced its financial results for the second quarter and six months ended June 30, 2016.
Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that the …
Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial …
Healthcare analysts shed light on vaccine maker Novavax, Inc. (NASDAQ:NVAX), and Israeli biotech firm Can-Fite Biopharma Ltd (NYSE:CANF).
Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment …
Although early stage biopharma companies do not make a profit, their pipeline study updates can send shares soaring… or crashing. Analysts weigh in …
